

ASX ANNOUNCEMENT

APPENDIX 4C – QUARTERLY CASH FLOW

31 July 2015: Brisbane, Australia - Analytica Ltd (ASX: ALT) manufacturer of the PeriCoach System, presents its Appendix 4C for the quarter ended 30th June 2015.

Major Milestones

- PeriCoach released in the United States of America and the United Kingdom during World Continnence Week
- Newswire picks up PeriCoach release and publishes (x3) on billboard in Times Square New York City
- Increasing sales and market awareness in Australia
- Launch of United States and United Kingdom marketing campaigns
- PeriCoach showcased at Clinician conferences, major Pregnancy and Baby Shows with strong interest and direct sales
- Digital awareness campaign enhanced and extended

Improving pelvic muscle strength, demonstrated by graphing exercise sessions (below), combined with strong testimonials of support, highlight the difference PeriCoach is making in women's lives.

Clinical papers and video testimonials by clinicians both in Australia and the USA continue to support the medical validation of the PeriCoach.


Personal recommendation continues to gain traction with PeriCoach's marketing strategy underpinning that objective.

Patients continue to be recruited in the company's multicentre clinical trial. The trial's primary endpoint seeks to validate that the PeriCoach system will enable the correct performance of pelvic floor exercises resulting in an improvement in Stress Urinary Incontinence. A secondary endpoint aims to demonstrate improved sexual function as a result of performing effective pelvic floor exercises.

Expenditure on marketing (\$801k), staff costs (\$330k), and research and development (\$120k) account for the bulk of the operating cash flows for the quarter. Sales accounted for 36k of income.


The company continues to have access to a line of credit of \$400k.

Analytica is seeking to raise up to \$3.76m by way of an underwritten (\$2.8m) 1:2 rights issue of 469.6m shares. For every 3 shares subscribed shareholders will be granted 2 options. Short dated option exercisable @ 1.1c by 28February 2016 and a long dated option exercisable @ 1.4c 28 February 2018. This offer will close on the 4th August.




"The PeriCoach has helped me to continue an active and healthy lifestyle. Using the PeriCoach for regular and consistent Kegel exercises has helped me avoid surgery for P.O.P. and eliminated the need to use a pessary."

Louise - Illinois, United States



"The best part of the PeriCoach is the feedback and the ability to actually visualize your strength of contractions and how long you can maintain it without the worry of counting seconds and repetitions. The app is great and is almost akin to other games available on android... it appeals to our generation's competitive nature and the desire to keep beating our highest score"


Rebecca - Queensland



"I think PeriCoach is one of the best things I have ever used. I use it twice a day, and love the reminder when I've missed out for 24 hours. It helps me to stay motivated, and I think I have done more exercises that I would have done, due to the feedback. I have quite a weak muscle and after 3

"I was stunned at how quickly this improvement had happened"

S.R. - South Australia



weeks using the PeriCoach, I noticed a difference. I have a moderate prolapse, and stress urinary incontinence, and both have improved in 3 weeks"

South Australia

Dr Michael Monsour

Chairman, Board of Directors

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

30/6/2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	36	68
1.2 Payments for		
(a) staff costs	(330)	(1,298)
(b) advertising and marketing	(801)	(2,056)
(c) research and development	(120)	(1,234)
(d) leased assets	-	-
(e) other working capital	(247)	(1,184)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	22	51
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income		
(b) R & D Tax Concession	0	988
(c) Royalty Income	0	6
(d) Other Grant Income	-	-
Net operating cash flows	(1,440)	(4,659)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter \$A'000	Year to date (12 months) \$A'000
1.8	Net operating cash flows (carried forward)	(1,440)	(4,659)
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	(11)	(11)
	(d) physical non-current assets	-	(42)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	(28)	(28)
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes)	-	-
	Net investing cash flows	(39)	(81)
1.14	Total operating and investing cash flows	(1,479)	(4,740)
Cash flows related to financing activities			
1.15	Proceeds from issues of shares	-	3714
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings:	-	-
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	(3)	(367)
	Net financing cash flows	(3)	3347
	Net increase (decrease) in cash held	(1,482)	(1,393)
1.21	Cash at beginning of quarter/year to date	2036	1,947
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	554	554

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	82
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	0
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	554	2,036
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	554	2,036

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:

Date: 31 July 2015

Print name: Dr Michael Monsour

+ See chapter 19 for defined terms.